Three-antibody classifier for muscle invasive urothelial carcinoma and its correlation with p53 expression
© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ..
AIMS: To assess the utility of a three-antibody immunohistochemistry panel to classify muscle invasive bladder cancers (MIBCs) in correlation with morphological features and p53 status.
METHODS: A retrospective review of 243 chemotherapy naïve MIBC cystectomy specimens was performed to assess morphological features. A tissue microarray was sequentially stained with CK5/6, GATA-3 and p16. Subgroups were assigned as basal-like (CK5/6+, GATA3-) and luminal (CK5/6-, GATA3+), with the latter subdivided into genomically unstable (GU, p16+) and urothelial like (Uro, p16-) subgroups. p53 staining was assessed as abnormal/wild type. Cases from the The Cancer Genome Atlas (TCGA) portal were assessed as external validation.
RESULTS: We identified 78.8% luminal, 21.2% basal cases within our cohort and 63.4% luminal, 36.6% basal in the TCGA dataset. Divergent differentiation (p<0.001) was significantly associated with basal-subtype cases in both cohorts. Within the luminal subgroup (n=186), 81 cases were classified as GU and 105 as Uro. Abnormal p53 staining was noted in 48.0% of basal, 80.2% GU and 38.1% Uro cases. Further, basal-subtype tumours significantly correlated with disease-specific death compared with Uro cases in multivariate survival analysis.
CONCLUSIONS: This retrospective study demonstrates the potential utility of a three-antibody immunohistochemistry panel to differentiate luminal and basal MIBC.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:75 |
|---|---|
| Enthalten in: |
Journal of clinical pathology - 75(2022), 11 vom: 08. Nov., Seite 766-771 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Olkhov-Mitsel, Ekaterina [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biomarkers, Tumor |
|---|
| Anmerkungen: |
Date Completed 21.10.2022 Date Revised 21.10.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1136/jclinpath-2021-207573 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM326514864 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM326514864 | ||
| 003 | DE-627 | ||
| 005 | 20231225194750.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1136/jclinpath-2021-207573 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1088.xml |
| 035 | |a (DE-627)NLM326514864 | ||
| 035 | |a (NLM)34103388 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Olkhov-Mitsel, Ekaterina |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Three-antibody classifier for muscle invasive urothelial carcinoma and its correlation with p53 expression |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 21.10.2022 | ||
| 500 | |a Date Revised 21.10.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ. | ||
| 520 | |a AIMS: To assess the utility of a three-antibody immunohistochemistry panel to classify muscle invasive bladder cancers (MIBCs) in correlation with morphological features and p53 status | ||
| 520 | |a METHODS: A retrospective review of 243 chemotherapy naïve MIBC cystectomy specimens was performed to assess morphological features. A tissue microarray was sequentially stained with CK5/6, GATA-3 and p16. Subgroups were assigned as basal-like (CK5/6+, GATA3-) and luminal (CK5/6-, GATA3+), with the latter subdivided into genomically unstable (GU, p16+) and urothelial like (Uro, p16-) subgroups. p53 staining was assessed as abnormal/wild type. Cases from the The Cancer Genome Atlas (TCGA) portal were assessed as external validation | ||
| 520 | |a RESULTS: We identified 78.8% luminal, 21.2% basal cases within our cohort and 63.4% luminal, 36.6% basal in the TCGA dataset. Divergent differentiation (p<0.001) was significantly associated with basal-subtype cases in both cohorts. Within the luminal subgroup (n=186), 81 cases were classified as GU and 105 as Uro. Abnormal p53 staining was noted in 48.0% of basal, 80.2% GU and 38.1% Uro cases. Further, basal-subtype tumours significantly correlated with disease-specific death compared with Uro cases in multivariate survival analysis | ||
| 520 | |a CONCLUSIONS: This retrospective study demonstrates the potential utility of a three-antibody immunohistochemistry panel to differentiate luminal and basal MIBC | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a immunohistochemistry | |
| 650 | 4 | |a molecular | |
| 650 | 4 | |a morphology | |
| 650 | 4 | |a pathology | |
| 650 | 4 | |a urinary bladder | |
| 650 | 7 | |a Biomarkers, Tumor |2 NLM | |
| 650 | 7 | |a Tumor Suppressor Protein p53 |2 NLM | |
| 700 | 1 | |a Hodgson, Anjelica |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Stanley K |e verfasserin |4 aut | |
| 700 | 1 | |a Vesprini, Danny |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Bin |e verfasserin |4 aut | |
| 700 | 1 | |a Downes, Michelle R |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical pathology |d 1947 |g 75(2022), 11 vom: 08. Nov., Seite 766-771 |w (DE-627)NLM000031372 |x 1472-4146 |7 nnns |
| 773 | 1 | 8 | |g volume:75 |g year:2022 |g number:11 |g day:08 |g month:11 |g pages:766-771 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1136/jclinpath-2021-207573 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 75 |j 2022 |e 11 |b 08 |c 11 |h 766-771 | ||